Access cutting-edge idiopathic pulmonary fibrosis treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access idiopathic pulmonary fibrosis specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related idiopathic pulmonary fibrosis treatment provided free
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Sponsor: Vicore Pharma AB
Check if you qualify for this idiopathic pulmonary fibrosis clinical trial in Birmingham, AL
If you're searching for idiopathic pulmonary fibrosis treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced idiopathic pulmonary fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.